Form 4: McKesson Director Kevin Ozan Receives Annual RSU Grant

McKesson Corporation Director Kevin Ozan was granted 301 Restricted Stock Units as part of an annual grant under the company's 2022 Stock Plan.

Summary

• Kevin M. Ozan, a Director of McKesson Corp (MCK), received a grant of 301 Restricted Stock Units (RSUs).
• The RSUs were granted under the company's 2022 Stock Plan as an annual grant.
• The RSUs vested immediately on July 30, 2025.
• Receipt of the underlying 301 common shares is deferred until Mr. Ozan leaves the Board.
• The transaction price for the RSUs was $0.

Sentiment

Score: 7

Explanation: The filing reports a standard equity grant to a director, which is a positive for corporate governance and aligns the director's interests with shareholders, but it does not contain significant new financial or operational information.

Positives

• The grant of Restricted Stock Units to a director aligns the director's long-term interests with those of the shareholders.
• Immediate vesting of the RSUs indicates a commitment to the director's continued service and contribution to the company.

Negatives

• The director will not receive the underlying shares immediately, as their receipt is deferred until departure from the Board, meaning no immediate liquidity from this grant.

Future Outlook

The deferral of share receipt until the Director leaves the Board indicates an expectation of continued service from Mr. Ozan, aligning his long-term commitment with the company's future performance.

Industry Context

This filing represents a routine equity compensation disclosure for a director, which is a common practice across the healthcare distribution industry and broader corporate landscape. Such grants are standard mechanisms for attracting and retaining qualified board members and aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• Equity compensation for directors, such as Restricted Stock Units, is a standard practice across various industries, including healthcare distribution.
• Companies like Cardinal Health (CAH) and AmerisourceBergen (ABC), direct competitors to McKesson, also utilize similar equity-based incentive plans for their directors to align interests and provide long-term incentives.
• The structure of immediate vesting with deferred share delivery until board departure is a common approach for director compensation, designed to ensure continued engagement and long-term alignment.

Corporate Governance

Related Party Transactions

• Grant of 301 Restricted Stock Units to Kevin M. Ozan, a Director of McKesson Corporation, as part of his annual compensation under the 2022 Stock Plan. This is a standard compensation arrangement for board members.

Stakeholder Impact

• Shareholders: Interests are aligned with the director through equity compensation, potentially fostering long-term value creation.
• Employees: No direct impact mentioned in this filing.
• Customers: No direct impact mentioned in this filing.
• Suppliers: No direct impact mentioned in this filing.
• Creditors: No direct impact mentioned in this filing.

Next Steps

• Mr. Ozan will receive the underlying 301 common shares upon his departure from the McKesson Board.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director, which is a standard practice for aligning management and board interests with shareholders. It does not provide new information that would significantly alter the investment thesis for McKesson Corporation, thus a 'hold' recommendation is appropriate.

Keywords

McKesson, MCK, Kevin Ozan, Director, Restricted Stock Units, RSU, Stock Plan, Insider Transaction, Corporate Governance, Compensation